It is well known that Parkinson's disease (PD) is caused by degeneration of nigrostriatal 16 dopaminergic neurons as well as several neurotransmitter pathways, especially the serotonergic 17 network. However, the significance and the contribution of these neuronal networks to various 18 aspects of PD remain enigmatic. In turn, the involvement of different neuronal networks leads to a 19 large number of motor and non-motor symptoms characterizing this disease. Serotonergic 20 dysfunction has been related to a variety of motor (e.g. dyskinesia) and non-motor symptoms (e.g.. 21 sleep difficulties, fatigue, depression). 22
Neurophysiological studies using different techniques and basic science studies have investigated 23 the role of the serotonergic degeneration in PD. The involvement of serotonergic neurons in the 24 pathophysiology of this movement disorder has been showed in animal studies. 1 Much of what is 25 currently known about the role of this network in the pathophysiology of PD is derived from 26 research combining neurophysiological techniques with behavioral measures of movement. In 27 addition, behavioral and neurophysiology studies in clinical populations with the basal ganglia 28 affected such as PD have been critical in advancing our understanding of the serotonergic system. 29
Determining how serotonergic neurons contribute to specific aspects of motor and non-motor 30 symptoms of PD will help in understanding how the serotonergic system contributes to the clinical 31 phenotype of PD. Both animal and human research is critical to developing a thorough 32 understanding of this topic. Furthermore, neurophysiological methods that consider the sensory-33 motor and connected biological system as a whole, including auditory evoked potentials, are 34 integral to advancing knowledge on this topic. 35
In this regard, there were two unanswered questions regarding the serotonergic system in PD. Does 36 the age of PD onset influence the involvement of serotonergic system? In other words, is there any 37 difference between early onset and late onset PD in serotonergic neurodegeneration, which might 38 explain differences in their clinical features? Additionally, what is the impact of dopaminergic 39 medications on this network? Understanding these two aspects is important in developing curative 40 therapies as well as improving symptomatic management of PD.
In this issue, Park and colleagues applied a neurophysiology protocol based on loudness 42 dependence of the auditory evoked potentials (LDAEP) to investigate the central serotonergic 43 neurotrasmission since it is well known serotonergic innervation is particularly high in the auditory 44 cortex. 2 Overall, these authors aimed to test the two research questions listed above. 2 LDAEP was 45 measured using N100 as well as P200 amplitude elicited by auditory stimuli as previously evaluated 46 in PD by Beucke et al. 3 
47
The study was performed on 30 mediation naïve PD patients divided two groups: early (< 69 years) 48 and late onset PD (> 70 years). This innovative study found that the absolute values of pre-49 treatment N1/P2 LDAEP and post-treatment N1 LDAEP (12 weeks after dopaminergic treatment) 50 were lower in the early-onset group than in the late-onset group, suggesting that central serotonergic 51 activity was more preserved in the early-onset compared to the late-onset group. Moreover, the 52 authors found that dopaminergic medications normalized the N1 LDAEP causing significant 53 amplitude decrease after 12 weeks of treatment. 54
These findings might explain some phenotypic differences related to the age of onset in PD. In 55 particular, levodopa-induced dyskinesias have recently been showed to be associated with lost of 56 balance between serotonin and dopamine neurotransmission with a longer preserved serotonin 57 activity in the presence of earlier dopaminergic degeneration. 4 Indeed, an enhanced striatal 58 serotonergic innervation is a proposed compensatory mechanism for the dopaminergic deficit. 5 59
Consequentially, these results should lead to research studies to develop new treatments for 60 dyskinesia targeting specifically on the serotonin activity. Moreover, LDAEP is a promising 61 neurophysiological biomarker of serotonin neurotransmission which may be used to identify 62 patients that may be helped by new therapies. However, the timing of serotonergic system 63 degeneration in the course of PD is still under debate. 64 A recent study on the status of striatal serotonergic innervations in MPTP-intoxicated monkeys at 65 different stages of experimental parkinsonism did not find any changes in serotonin positive axonal 66 density in the caudate or putamen, in either the pre-symptomatic or symptomatic stages of 67 parkinsonism, not supporting a compensatory role for the striatal serotonergic system. 6 However, it 68 is well known that the serotonergic dysfunction in PD involves not only the basal ganglia but also 69 other regions, such as the raphe nuclei. In this regard, Pasquini et al have recently showed that about 70 four years after diagnosis, raphe serotonin transporter availability was significantly reduced in more 71 than one third of PD patients without correlation to non-motor symptoms but with a correlation to 72 tremor severity. 7,8 73
Park and colleagues tried to explore the role played by dopaminergic agents on the serotonin 74 system. The study showed that dopaminergic treatments change the pathologically high LDAEP. 75
Consequentially, dopaminergic therapies might be optimized to improve the serotonergic activity by 76 measuring changes of LDAEP as a disease biomarker. Moreover, measuring serotonergic activity 77 through LDAEP may be helpful to avoid damage of serotonergic neurons due to high 78 pharmacological dopaminergic stimulation. 79
While the findings of Park et al. are intriguing, it would be interesting to perform a similar study 80 with an age matched control group to rule out a potential role of age in the serotonin system 81 degeneration that might explain the differences in serotonergic activity between the early and late 82 onset PD patients. Moreover, there is still a lack of consensus in the age definition of early and late 83 onset PD. This effect of age on the serotonergic system and the arbitrary choice of the age to 84 identify early onset and late onset PD may underlie the contrasting results among different studies. 85 However, it is likely that further progresses in animal studies, neuroimaging techniques, basal 86 ganglia connectivity and computational processing will find their way to clinical practice and open 87 up a plethora of research possibilities in the coming decade. 88 https://doi.org/10.1017/cjn.2020.11 Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 31 Jan 2020 at 08:15:59, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
